Found 1412 results
[ Author(Desc)] Title Type Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
B
L. E. Bermudez and Young, L. S., Natural killer cell-dependent mycobacteriostatic and mycobactericidal activity in human macrophages., Journal of immunology (Baltimore, Md. : 1950), vol. 146, no. 1, pp. 265-70, 1991.
L. E. Bermudez, Motamedi, N., Chee, C., Baimukanova, G., Kolonoski, P., Inderlied, C., Aralar, P., Wang, G., Phan, L. Tam, and Young, L. S., EDP-420, a bicyclolide (bridged bicyclic macrolide), is active against Mycobacterium avium., Antimicrobial agents and chemotherapy, vol. 51, no. 5, pp. 1666-70, 2007.
L. E. Bermudez, Inderlied, C. B., Kolonoski, P., Petrofsky, M., Aralar, P., Wu, M., and Young, L. S., Activity of moxifloxacin by itself and in combination with ethambutol, rifabutin, and azithromycin in vitro and in vivo against Mycobacterium avium., Antimicrobial agents and chemotherapy, vol. 45, no. 1, pp. 217-22, 2001.
L. E. Bermudez, Kolonoski, P., and Young, L. S., Natural killer cell activity and macrophage-dependent inhibition of growth or killing of Mycobacterium avium complex in a mouse model., Journal of leukocyte biology, vol. 47, no. 2, pp. 135-41, 1990.
L. E. Bermudez, [Use of monoclonal antibodies in the diagnosis and treatment of infection in immunocompromised patients]., Revista paulista de medicina, vol. 105, no. 6, pp. 341-6, 1987.
L. E. Bermudez, Kolonoski, P., Seitz, L. E., Petrofsky, M., Reynolds, R., Wu, M., and Young, L. S., SRI-286, a thiosemicarbazole, in combination with mefloquine and moxifloxacin for treatment of murine Mycobacterium avium complex disease., Antimicrobial agents and chemotherapy, vol. 48, no. 9, pp. 3556-8, 2004.
L. E. Bermudez, Wu, M., and Young, L. S., Interleukin-12-stimulated natural killer cells can activate human macrophages to inhibit growth of Mycobacterium avium., Infection and immunity, vol. 63, no. 10, pp. 4099-104, 1995.
L. E. Bermudez, Kolonoski, P., Petrofsky, M., Wu, M., Inderlied, C. B., and Young, L. S., Mefloquine, moxifloxacin, and ethambutol are a triple-drug alternative to macrolide-containing regimens for treatment of Mycobacterium avium disease., The Journal of infectious diseases, vol. 187, no. 12, pp. 1977-80, 2003.
L. E. Bermudez, Inderlied, C. B., and Young, L. S., Mycobacterium avium complex in AIDS., Current clinical topics in infectious diseases, vol. 12, pp. 257-81, 1992.
L. E. Bermudez, Wu, M., Miltner, E., and Inderlied, C. B., Isolation of two subpopulations of Mycobacterium avium within human macrophages., FEMS microbiology letters, vol. 178, no. 1, pp. 19-26, 1999.
L. E. Bermudez, Motamedi, N., Kolonoski, P., Chee, C., Baimukanova, G., Bildfell, R. J., Wang, G., Phan, L. Tam, and S Lowell, Y., The efficacy of clarithromycin and the bicyclolide EDP-420 against Mycobacterium avium in a mouse model of pulmonary infection., The Journal of infectious diseases, vol. 197, no. 11, pp. 1506-10, 2008.
L. E. Bermudez, Young, L. S., and Inderlied, C. B., Rifabutin and sparfloxacin but not azithromycin inhibit binding of Mycobacterium avium complex to HT-29 intestinal mucosal cells., Antimicrobial agents and chemotherapy, vol. 38, no. 5, pp. 1200-2, 1994.
L. E. Bermudez, Young, L. S., and Gupta, S., 1,25 Dihydroxyvitamin D3-dependent inhibition of growth or killing of Mycobacterium avium complex in human macrophages is mediated by TNF and GM-CSF., Cellular immunology, vol. 127, no. 2, pp. 432-41, 1990.
L. E. Bermudez, Sangari, F. J., and Parker, A., Green fluorescent protein in the measurement of bacteria-host interactions., Methods in enzymology, vol. 302, pp. 285-95, 1999.
L. E. Bermudez, Parker, A., and Goodman, J. R., Growth within macrophages increases the efficiency of Mycobacterium avium in invading other macrophages by a complement receptor-independent pathway., Infection and immunity, vol. 65, no. 5, pp. 1916-25, 1997.
L. E. Bermudez, Wu, M., Enkel, H., and Young, L. S., Naturally occurring antibodies against Mycobacterium avium complex., Annals of clinical and laboratory science, vol. 19, no. 6, pp. 435-43, 1989.
L. E. Bermudez, [Post-antibiotic effect in the treatment of infections in neutropenic patients]., Revista do Hospital das Clínicas, vol. 41, no. 2, pp. 76-9, 1986.
L. E. Bermudez, Nash, K. A., Petrofsky, M., Young, L. S., and Inderlied, C. B., Effect of ethambutol on emergence of clarithromycin-resistant Mycobacterium avium complex in the beige mouse model., The Journal of infectious diseases, vol. 174, no. 6, pp. 1218-22, 1996.
L. E. Bermudez and Yamazaki, Y., Effects of macrolides and ketolides on mycobacterial infections., Current pharmaceutical design, vol. 10, no. 26, pp. 3221-8, 2004.
L. E. Bermudez, Wu, M., Petrofsky, M., and Young, L. S., Interleukin-6 antagonizes tumor necrosis factor-mediated mycobacteriostatic and mycobactericidal activities in macrophages., Infection and immunity, vol. 60, no. 10, pp. 4245-52, 1992.
L. E. Bermudez and Young, L. S., Ethanol augments intracellular survival of Mycobacterium avium complex and impairs macrophage responses to cytokines., The Journal of infectious diseases, vol. 163, no. 6, pp. 1286-92, 1991.
L. E. Bermudez and Petrofsky, M., Host defense against Mycobacterium avium does not have an absolute requirement for major histocompatibility complex class I-restricted T cells., Infection and immunity, vol. 67, no. 6, pp. 3108-11, 1999.
L. E. Bermudez, Inderlied, C. B., Kolonoski, P., Petrofsky, M., and Young, L. S., Clarithromycin, dapsone, and a combination of both used to treat or prevent disseminated Mycobacterium avium infection in beige mice., Antimicrobial agents and chemotherapy, vol. 38, no. 12, pp. 2717-21, 1994.
L. E. Bermudez and Young, L. S., Killing of Mycobacterium avium: insights provided by the use of recombinant cytokines., Research in microbiology, vol. 141, no. 2, pp. 241-3, 1990.
L. E. Bermudez, Wu, M., and Young, L. S., Intracellular killing of Mycobacterium avium complex by rifapentine and liposome-encapsulated amikacin., The Journal of infectious diseases, vol. 156, no. 3, pp. 510-3, 1987.

Pages